Your browser doesn't support javascript.
loading
Prevalence of exocrine pancreatic insufficiency in patients with chronic pancreatitis without follow-up. PANCR-EVOL Study / Prevalencia de insuficiencia pancreática exocrina en pacientes con pancreatitis crónica sin segruimiento. Estudio PANCR-EVOL
Marra-Lopez Valenciano, Carlos; Bolado Concejo, Federico; Marín Serrano, Eva; Millastre Bocos, Judith; Martínez-Moneo, Emma; Pérez Rodríguez, Esperanza; Francisco González, María; Pozo-García, Andrés del; Hernández Martín, Anaiansi; Labrador Barba, Elena; Orera Peña, María Luisa; de-Madaria, Enrique.
Afiliação
  • Marra-Lopez Valenciano, Carlos; Complejo Hospitalario de Navarra. Digestive Service. Pamplona. Spain
  • Bolado Concejo, Federico; Complejo Hospitalario de Navarra. Digestive Service. Pamplona. Spain
  • Marín Serrano, Eva; Hospital La Paz. Digestive Service. Madrid. Spain
  • Millastre Bocos, Judith; Hospital Universitario Miguel Servet. Digestive Service. Zaragoza. Spain
  • Martínez-Moneo, Emma; Hospital Universitario de Cruces. Digestive Service. Spain
  • Pérez Rodríguez, Esperanza; Hospital Universitario Reina Sofia. Digestive Service. Córdoba. Spain
  • Francisco González, María; Complejo Hospitalario Universitario de Orense. Digestive Service. Orense. Spain
  • Pozo-García, Andrés del; Hospital 12 de Octubre. Digestive Service. Madrid. Spain
  • Hernández Martín, Anaiansi; Hospital San Eloy. Digestive Service. Spain
  • Labrador Barba, Elena; Medical Department Mylan. Spain
  • Orera Peña, María Luisa; Medical Department Mylan. Spain
  • de-Madaria, Enrique; Hospital General Universitario de Alicante. Department of Gastroenterology. Alicante. Spain
Gastroenterol. hepatol. (Ed. impr.) ; 41(2): 77-86, feb. 2018. tab
Article em En | IBECS | ID: ibc-170925
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
Background/objectives. Exocrine pancreatic insufficiency (EPI) is an important complication of chronic pancreatitis (CP). Guidelines recommend to rule out EPI in CP, to detect those patients who would benefit from pancreatic enzyme replacement therapy. The aim of this study was to evaluate the prevalence of EPI in patients with CP without follow-up in the last 2 years and to describe their nutritional status and quality of life (QoL). Methods. This was a cross-sectional, multicenter Spanish study. CP patients without follow-up by a gastroenterologist or surgeon in at least 2 years were included. EPI was defined as fecal elastase test <200mcg/g. For nutritional assessment, laboratory and anthropometric data were obtained. QoL was investigated using the EORTC QLQ-C30 questionnaire. Results. 64 patients (mean age 58.8±10.3 years, 85.9% men) from 10 centers were included. Median time since diagnosis of CP was 58.7 months [37.7-95.4]. Forty-one patients (64.1%) had EPI. Regarding nutritional status, the following differences were observed (EPI vs. Non-EPI) BMI (23.9±3.5kg/m2 vs. 25.7±2.5, p=0.03); glucose (121 [96-189] mg/dL vs. 98 [90-116], p=0.006); HbA1c 6.6% [6.0-8.4] vs. 5.5 [5.3-6.0], p=0.0005); Vitamin A (0.44mg/L [0.35-0.57] vs. 0.53 [0.47-0.63], p=0.048) and Vitamin E (11.2±5.0μg/ml vs. 14.4±4.3, p=0.03). EPI group showed a worse EORTC QLQ-C30 score on physical (93.3 [66.7-100] vs. 100 [93.3-100], p=0.048) and cognitive function (100 [83.3-100] vs. 100 [100-100], p=0.04). Conclusions. Prevalence of EPI is high in patients with CP without follow-up. EPI group had higher levels of glucose, lower levels of vitamins A and E and worse QoL (AU)
RESUMEN
Antecedentes/objetivos. la insuficiencia pancreática exocrina (IPE) es una importante complicación de la pancreatitis crónica (PC). Las guías recomiendan el seguimiento de la IPE en PC, para identificar a aquellos pacientes que puedan beneficiarse del tratamiento enzimático sustitutivo. El objetivo de este estudio fue evaluar la prevalencia de IPE en pacientes con PC sin seguimiento en los últimos 2 años y describir su estado nutricional y calidad de vida (QoL). Métodos. estudio trasversal, multicéntrico, español. Se incluyeron pacientes con PC sin seguimiento por un gastroenterólogo/cirujano en los últimos 2años. Se definió IPE como elastasa fecal<200mcg/g. Se recogieron parámetros de laboratorio y datos antropométricos para el análisis nutricional. Para la evaluación de QoL se utilizó el cuestionario EORTC QLQ-C30. Resultados. se incluyeron prospectivamente 64 pacientes (58,8±10,3 años, media 85,9%) de 10 centros. Tiempo medio desde el diagnóstico de PC 58,7meses [37,7-95,4]. 41 pacientes (64,1%) tenían IPE. Estado nutricional se observaron las siguientes diferencias (IPE vs No-IPE) IMC (23,9±3,5kg/m2 vs. 25,7±2,5,p=0,03); glucosa 121 [96-189] mg/dL vs. 98 [90-116];p =0,006); HbA1c 6,6% [6,0-8,4] vs. 5,5 [5,3-6,0],p=0,0005); Vitamina-A (0,44mg/L [0,35-0,57] vs. 0,53 [0,47-0,63],p=0,048), Vitamina-E (11,2±5,0μg/ml vs. 14,4±4,3,p=0,03). El grupo de IPE mostró una peor puntuación en el EORTC QLQ-C30 en las funciones física (93,3 [66,7-100] vs. 100 [93,3-100], p=0,048) y cognitiva (100 [83,3-100] vs. 100 [100-100],p=0,04). Conclusiones. la prevalencia de IPE en pacientes con PC sin seguimiento es elevada. En el grupo de IPE se observaron niveles elevados de glucosa, bajos de vitaminas A y E y peor calidad de vida (AU)
Assuntos

Texto completo: 1 Coleções: 06-national / ES Base de dados: IBECS Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 06-national / ES Base de dados: IBECS Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article